Hubei Biocause Heilen Pharmaceutical Co., Ltd.
301211.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.32B
Close$
$2.17
81.8% downside
Current Fair Value
81.8% downsideOvervalued by 81.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.32 Billion |
|---|---|
| Enterprise Value | $4.92 Billion |
| Dividend Yield | $0.06 (0.47%) |
| Earnings per Share | $0.1 |
| Beta | 0.54 |
| Outstanding Shares | 417,600,000 |
Return
| Return on Equity | 2.04% |
|---|---|
| Return on Assets | 1.94% |
| Return on Invested Capital | 1.97% |
Valuation & Multiples
| P/E Ratio | 108.42 |
|---|---|
| PEG | 70.2 |
| Price to Sales | 11.87 |
| Price to Book Ratio | 2.37 |
| Enterprise Value to Revenue | 10.56 |
| Enterprise Value to EBIT | 108.98 |
| Enterprise Value to Net Income | 105 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hubei Biocause Heilen Pharmaceutical Co., Ltd.
952 employees
CEO: Qun Liang Hubei Biocause Heilen Pharmaceutical Co., Ltd. is a Chinese enterprise with diverse operations spanning the pharmaceutical, chemical, and new energy fuel sectors. Within its pharmaceutical segment, the company manufactures active pharmac...